Inhaled and nasal corticosteroidsFactors affecting the risks of systemic adverse effects

Pharmacology and Therapeutics

Volumn 83, Issue 3, 1999, Pages 153-179

  Cave, Alison ^a   Arlett, Peter ^a   Lee, Ennis ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

Adrenal suppression; Bone mineral density; Cataracts; Glaucoma; Growth retardation; Osteoporosis

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BETAMETHASONE; BUDESONIDE; CORTICOSTEROID; CORTICOSTEROID RECEPTOR; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUTICASONE PROPIONATE; FORMOTEROL; MOMETASONE FUROATE; PREDNISOLONE; PREDNISONE; TRIAMCINOLONE ACETONIDE; ANTIINFLAMMATORY AGENT; CORTICOTROPIN; HYDROCORTISONE;

ADRENAL SUPPRESSION; ASTHMA; BONE MINERAL; CATARACT; DRUG SAFETY; GLAUCOMA; GROWTH RETARDATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; NOTE; OSTEOPOROSIS; PRIORITY JOURNAL; RHINITIS; ADULT; BLOOD; BONE DENSITY; CHEMICALLY INDUCED DISORDER; CHILD; DRUG EFFECT; GROWTH; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; PRESCHOOL CHILD; REVIEW; UNITED KINGDOM; URINE;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; ADRENOCORTICOTROPIC HORMONE; ADULT; ANTI-INFLAMMATORY AGENTS; BONE DENSITY; CATARACT; CHILD; CHILD, PRESCHOOL; GLAUCOMA; GREAT BRITAIN; GROWTH; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM;

EID: 0032589989     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(99)00019-4     Document Type: Review

References (126)

1. Adamsons I., Munoz B., Enger C., Taylor H.R. Prevalence of lens opacities in surgical and general populations. Arch Ophthalmol. 109:1991;993-997.
2. Adcock I.M., Bronnegard M., Barnes P.J. Glucocorticoid receptor mRNA localization and expression in human lung. Am Rev Respir Dis. 143:1991;A628.
3. Adinoff A.D., Hollister J.R. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med. 309:1983;265-268.
4. Agertoft L., Pedersen S. Bone densitometry in children treated for 3-6 years with high dose inhaled BUD. Eur Respir J. 6(suppl. 17):1993;261S.
5. Agertoft L., Pedersen S. Relationship between short term lower leg growth and long term statural growth in asthmatic children treated with BUD. Eur Respir J. 9:1996;294S.
6. Allen D.B. Growth suppression by glucocorticoid therapy. Endocrinol Metab Clin North Am. 25:1996;699-717.
7. Allen D.B., Mullen M., Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol. 93:1994;967-976.
8. Allen M.B., Ray S.G., Leitch A.G., Dhillon B., Cullen B. Steroid aerosols and cataract formation. Br Med J. 299:1989;432-433.
9. Armaly, M. F. (1986). Corticosteroid glaucoma. In J. E. Cairns (Ed.), Glaucoma (pp. 697-710). London: Grune & Stratton.
10. Ayres J.G., Bateman E.D., Lundback B., Harns T.A.J. High dose FP, 1 mg daily, versus FP, 2 mg daily, or BUD, 1.6 mg daily, in patients with severe chronic asthma. Eur Respir J. 8:1995;579-586.
11. Balfour-Lynn L. Growth and childhood asthma. Arch Dis Child. 61:1986;1049-1055.
12. Barnes N.C., Marone G., Di Maria G.U., Visser S., Utama I., Payne S.L. A comparison of FP, 1 mg daily, with BDP, 2 mg daily, in the treatment of severe asthma. Eur Respir J. 6:1993;877-884.
13. Barnes P.J., Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis. 148:1993;S1-S26.
14. Bisgaard H., Damkjaer Nielsen M., Andersen B., Andersen P., Foged N., Fuglsang G., Host A., Leth C., Pedersen M., Pelck I., Stafanger G., Osterballe O. Adrenal function in children with bronchial asthma with beclomethasone dipropionate or budesonide. J Allergy Clin Immunol. 81:1988;1088-1095.
15. Black R.L., Oglesby R.B., von Sallmann L., Bunim J.J. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA. 174:1960;166-171.
16. Boe J., Bakke P., Rodoleu T., Skovlund E., Gulsvik A. High dose inhaled steroids in asthmatics, moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA). axis. Eur Respir J. 7:1994;2179-2184.
17. Bootsma G.P., Dekhuijen P.N.R., Festen J., Mulder P.G.H., Swinkels L.M.J.W., van Herwaarden C.L.A. Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate. Am J Respir Crit Care Med. 153:1996;924-930.
18. Brannan M.D., Herron J.M., Reidenberg P., Affrime M.B. Lack of hypothalamic-pituitary-adrenal axis suppression with once-daily or twice-daily beclomethasone dipropionate aqueous nasal spray administered to patients with allergic rhinitis. Clin Ther. 17:1995;637-647.
19. Brannan M.D., Herron J.M., Reidenberg P., Affrime M.B. Lack of HPA suppression following 36 days of intranasal mometasone furoate. Ann Allergy Asthma Immunol. 78:1997;154.
20. Review and position statement. Thorax. 52:1997;S1-S21.
21. Brogan R.N., McTavish D. Budesonide, an update review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs. 44:1992;375-407.
22. Brown J.P., Delmas P.D., Malaval L., Edouard C., Chapuy M.C., Meunier P.J. Serum bone GIa protein, a specific marker for bone formation in postmenopausal osteoporosis. Lancet i. 1091-1093:1984.
23. Bucala R., Gallati M., Manabe S., Cotlier E., Cerami A. Glucocorticoid lens protein adducts in experimentally induced steroid cataracts. Exp Eye Res. 40:1985;853-863.
24. Chang C.C.C., Tam A.Y.C. Suppression of adrenal function in children on inhaled steroids. J Paediatr Child Health. 27:1991;232-234.
25. Clark D.J., Clark R.A., Lipworth B.J. Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children. Thorax. 51:1996;941-943. a.
26. Clark D.J., Grove A., Cargill R.I., Lipworth B.J. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax. 51:1996;262-266. b.
27. Corren J., Rachelefsky G., Hochhaus G. A five-way parallel randomized study to compare the safety profile of beclomethasone diprionate (BDP), budesonide (BUD), flunisolide (FLU), fluticasone propionate (FP), and triamcinolone acetonide (TA) in healthy male volunteers. Chest. 110:1998;83S.
28. The safety of inhaled and nasal corticosteroids. Curr Probl Pharmacovigilance. 24:1998;8.
29. Cumming R.G., Mitchell P., Leeder S.R. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 337:1997;8-14.
30. Davies R.J., Nelson H.S. Once-daily mometasone furoate nasal spray, efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis. Clin Ther. 19:1997;27-38.
31. Derendorf H., Hochhaus G., Meibohm B., Mollmann H., Barth J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol. 101:1998;S440-S446.
32. Dreyer E.B. Inhaled steroid use and glaucoma. N Engl J Med. 329:1993;1822.
33. Estelle F., Simons R., Persaud M.P., Gillespie C.A., Cheang M., Shuckett E.P. Absence of posterior subcapsular cataracts in young patients treated with inhaled corticosteroids. Lancet. 342:1993;776-778.
34. th Annual Meeting of the European Society of Pharmacovigilance, P058.
35. Fabbri L., Burge P.S., Croonenburgh L., Warlies F., Weeks B., Ciaccia A., Parker C. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax. 48:1993;817-823.
36. Falcoz C., Kirby S., Smith J., Olsson P., Ventresca G. Pharmacokinetics and systemic exposure of inhaled beclomethasone dipropionate. Eur Respir J. 17(suppl. 9):1996;162S.
37. Ferguson A.C., Murray A.B., Txe W.-J. Short stature and delayed skeletal maturation in children with allergic disease. J Allergy Clin Immunol. 69:1982;461-466.
38. Fireman P. Treatment strategies designed to minimize medical complications of allergic rhinitis. Am J Rhinol. 11:1997;95-102.
39. Flynn M.D., Beasley P., Tooke J.E. Adrenal suppression with intranasal betamethasone drops. J Laryngol Otol. 106:1992;827-828.
40. Fraunfelder F.T., Meyer S.M. Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids. Am J Ophthalmol. 109:1990;489-490.
41. Garbe E., LeLorier J., Boivin J.-F., Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA. 277:1997;722-727.
42. Godfrey S., Konig P. Beclomethasone dipropionate aerosol in childhood asthma. Arch Dis Child. 48:1973;665-670.
43. Goldstein D.E., Konig P. Effect of beclomethasone dipropionate on hypothalamic-pituitary-adrenal-axis function in children with asthma. Pediatrics. 72:1983;60-64.
44. Grahnen A., Eckernas S.A., Brundin R.M., Ling-Andersson A. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol. 38:1994;521-525.
45. Grove A., Allam C., McFarlane L.C., McPhate G., Jackson C.M., Lipworth B.J. A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects. Br J Clin Pharmacol. 38:1994;527-532.
46. Hanania N.A., Chapman K.R., Kesten S. Adverse effects of inhaled corticosteroids. Am J Med. 98:1995;196-208.
47. Harding S.M. The human pharmacology of fluticasone propionate. Respir Med. 84(suppl. A):1990;25-29.
48. Harris D.M., Martin L.E., Harrison C., Jack D. The effect of intranasal beclomethasone dipropionate on adrenal function. Clin. Allergy. 4:1974;291-294.
49. Hauspie R., Susanne C., Alexander F. A mixed longitudinal study of the growth height and weight in asthmatic children. Hum Biol. 48:1976;271-276.
50. Hodge W.G., Whitcher J.P., Satariano W. Risk factors for age-related cataracts. Epidemiol Res. 17:1995;336-346.
51. Holt P.R., Lowndes D.W., Smithies E., Dixon G.T. The effect of an inhaled steroid on the hypothalamic-pituitary-adrenal axis - which tests should be used? Clin Exp Allergy. 20:1990;145-149.
52. Ip M., Lam K., Yam L., Kung A., Bg M. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest. 105:1994;1722-1727.
53. Jennings B.H., Andersson K.E., Johansson S.A. Assessment of systemic effects of inhaled glucocorticoids, the influence of the frequency of blood sampling technique on plasma cortisol and leucocytes. Eur J Clin Pharmacol. 39:1990;127-131.
54. Jennings B.H., Andersson K.E., Johansson S.A. Assessment of systemic effects of inhaled glucocorticoids, comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur J Clin Pharmacol. 40:1991;77-82.
55. Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol. 97:1996;169-176.
56. Jones K.S., Hart L.L. Osteoporosis as a result of inhaled corticosteroids. Ann Pharmacol. 27:1993;1470-1472.
57. Kamada A.K., Szefler S.J., Martin R.J., Boushey H.A., Chinchilli V.M., Drazen J.M., Fish J.E., Israel E., Lazarus S.C., Lemanske R.F. Issues in the use of inhaled corticosteroids. The Asthma Clinical Research Network. Am J Respir Crit Care Med. 153:1996;1739-1748.
58. Kellerman D., Stricker W., Howland W., Sorkness C., Dockhorn R., Galant S., Vargas R., Hamedani A., Liao E. Effects of inhaled fluticasone propionate (FP). on the HPA axis of patients with asthma. Eur Respir J. 9(suppl. 23):1996;162s.
59. Kelly H.W. Comparison of inhaled corticosteroids. Ann Pharmacother. 32:1998;220-232.
60. Kerrebijn K.F. Beclomethasone dipropionate in long-term treatment of asthma in children. J Pediatr. 89:1976;821-826.
61. Knutsson U., Sderna P., Marcus C., Carlstedt-Duke J., Calrstrom K., Bronnegard M. Effects of intra-nasal corticosteroids on endogenous glucocorticoid peripheral and central function. J Endocrinol. 144:1995;301-310.
62. Leblanc P., Mink S., Keistinen T., Saarelainen P.A., Ringdal N., Payne S.L. A comparison of fluticasone propionate 200 μg/day with beclomethasone dipropionate 400μg/day in adult asthma. Allergy. 49:1994;380-385.
63. Lipworth B.J. Airway and systemic effects of inhaled corticosteroids in asthma, dose-response relationship. Pulm Pharmacol. 9:1996;19-27.
64. Lipworth B.J., Seckl J.R. Measures for detecting systemic bioactivity with inhaled and intra-nasal corticosteroids. Thorax. 52:1997;476-482.
65. Lipworth B.J., Clark D.J., McFarlane L.C. Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children. Thorax. 52:1997;686-689.
66. Littlewood J.M., Johnson A.W., Edwards P.A., Littlewood A.E. Growth retardation in asthmatic children treated with inhaled beclomethasone dipropionate. Lancet i. 115-116:1988.
67. MacKenzie C.A., Weinberg E.G., Tabachnik E., Taylor M., Havnen J., Crescenzi K. A placebo controlled trial of fluticasone propionate in asthmatic children. Eur J Pediatr. 152:1993;856-860.
68. Mackie A.C., Ventresca G.P., Fuller R.W., Bye A. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol. 41:1996;539-542.
69. 2-adrenoreceptor gene expression in human lung. Am Rev Respir Dis. 145:1992;A834.
70. Malm L., Wihl J.A. Intra-nasal beclomethasone dipropionate in vasomotor rhinitis. Acta Allergol. 31:1976;245-253.
71. Manabe S., Bucala R., Cerami A. Nonenzymatic addition of glucocorticoids to lens proteins in steroid-induced cataracts. J Clin Invest. 74:1984;1803-1810.
72. Marshall D.H., Crilly R., Nordin B.E. The relation between plasma androstenedione and oestrone levels in untreated and corticosteroid-treated post-menopausal women. Clin Endocrinol. 9:1978;407-412.
73. McGill K.A., Joesph B., Busse W.W. Corticosteroids in the treatment of asthma. Practical recommendations. Clin Immunother. 4:1995;16-48.
74. Meeran K., Hattersley A., Burrin J., Shiner R., Ibbertson K. Oral and inhaled corticosteroids reduce bone formation as shown by plasma osteocalcin levels. Am J Respir Crit Care Med. 151:1995;333-336.
75. Meibohm B., Hochhaus G., Rohatagi S., Mollmann H., Barth J., Wagner M., Krieg M., Stockmann R., Derendorf H. Dependency of cortisol depression on the administration time of inhaled corticosteroid. J Clin Pharmacol. 37:1997;704-710.
76. Miller-Larsson A., Mattsson H., Ohlsson S., Hjertberg E., Tunek A., Dahlback M., Brattsand R. Prolonged release from the airway tissue from glucocorticoids budesonide and fluticasone propionate as compared to beclomethasone dipropionate. Am J Respir Crit Care Med. 149(suppl. 4):1994;A466.
77. Mygind N., Hansen I.B. Beclomethasone dipropionate aerosol effect on the adrenals in normal persons. Acta Allergol. 28:1973;2110-2218.
78. Mygind N., Lund V. Topical corticosteroid therapy for rhinitis. A review. Clin Immunother. 2:1996;122-136.
79. Nassif E., Weiberger M., Sherman B., Brown K. Extrapulmonary effects of maintenance corticosteroids with alternate day prednisolone and inhaled beclomethasone dipropionate in children with chronic asthma. J Allergy Clin Immunol. 80:1987;518-529.
80. Newman S.P., Millar A.B., Lennard-Jones T.R., Moren F., Clarke S.W. Improvement of pressurized aerosol deposition with nebuhaler spacer device. Thorax. 39:1984;935-941.
81. Ninan T.K., Russell G. Asthma, inhaled corticosteroid treatment and growth. Arch Dis Child. 67:1992;703-705.
82. Noonan M., Chervinsky P., Busse W.W., Weisberg S.C., Pinnas J., De Boisblanc B.P., Boltansky H., Pearlman D., Repsher L., Kellerman D. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med. 152:1995;1467-1473.
83. Oberger E., Engstrom I., Karlberg J. Long term treatment with glucocorticoids/ACTH in asthmatic children. III. Effects on growth and adult height. Acta Paediatr Scand. 79:1990;77-83.
84. Opatowsky I., Feldman R.M., Gross R., Feldman S.T. Intraocular pressure elevation associated with inhalation and nasal corticosteroids. Ophthalmology. 102:1995;177-179.
85. Packe G.E., Robb O., Robins S.P., Reid D.M., Douglas J.G. Bone density in asthmatic patients taking inhaled corticosteroids, comparison of budesonide and beclomethasone dipropionate. J R Coll Physicians Lond. 30:1996;123-131.
86. Pedersen S. Pharmacokinetics of budesonide in children with asthma. Eur J Clin Pharmacol. 31:1987;579-582.
87. Phillip M., Aviram M., Leiberman E., Zadik Z., Giat Y., Levy J., Tal A. Integrated plasma cortisol concentration in children with asthma receiving long-term inhaled corticosteroids. Pediatrics. 81:1992;452-454.
88. Picado C., Luengo M. Corticosteroid-induced bone loss. Prevention and management. Drug Safety. 15:1996;347-359.
89. Pill M.W. Fluticasone propionate. pharmacology and efficacy Pharmacol Ther. 22:1997;86-92.
90. Pocock N.A., Eisman J.A., Dunstan C.R., Evans R.A., Thomas D.H., Huq N.L. Recovery from steroid-induced osteoporosis. Ann Intern Med. 107:1987;319-323.
91. Priftis K., Milner A.D., Conway E., Honour J.W. Adrenal function in asthma. Arch Dis Child. 65:1990;838-840.
92. Rachelefsky G.S., Chervinsky P., Meltzer E.O., Morris R.M., Selizer J.M., Skoner D.P., Storms W.W., Wood R.A. An evaluation of the effects of beclomethasone dipropionate aqueous nasal spray [vancenase AQ (VNS)] on long term growth in children. J Allergy Clin Immunol. 101:1998;S236.
93. Reed C.E. Aerosol glucocorticoid treatment of asthma, adult. Am Rev Respir Dis. 140:1990;S82-S88.
94. Robinson D.S., Geddes D.M. Inhaled corticosteroids, benefits and risks. J Asthma. 33:1996;5-16.
95. Ryrfeldt A., Andersson P., Edsbacker S., Tonnesson M., Davies D., Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis. 63(suppl. 122):1982;86-95.
96. Sambrook P.N., Jones G. Corticosteroid osteoporosis. Br J Rheumatol. 34:1995;8-12.
97. Shimura S., Sasaki T., Ikeda K., Yamauchi K., Sasaki H., Takishima T. Direct inhibitory action of glucocorticoid on glycoconjugate secretion from airway submucosal gland. Am Rev Respir Dis. 141:1990;1044-1099.
98. Shun-Shin G.A., Brown N.P., Bron A.J., Sparrow J.M. Dynamic nature of posterior subcapsular cataract. Br J Ophthalmol. 73:1989;522-527.
99. Skuta, G. L., & Morgan, R. K. (1996). Corticosteroid-induced glaucoma. In R. Ritch, M. B. Shields, & T. Kruptin (Eds.), The Glaucomas (pp. 1177-1188). St. Louis, MO: Mosby.
100. Slavin R.G., Allen I.E., Bernstein I.L., Blumenthal M.N., Bolin J.F., Ouellette J.J., Reed C.E., Oren J. Multicenter study of flunisolide aerosol in adult patients with steroid-dependent asthma. J Allergy Clin Immunol. 66:1980;379-385.
101. Smith M.J., Hodson M.E. Effects of long term inhaled high dose beclomethasone dipropionate on adrenal function. Thorax. 38:1983;676-681.
102. Sorkin S., Warren D. Probable adrenal suppression from intranasal beclomethasone dipropionate. J Fam Pract. 22:1986;449-450.
103. Stevens D.J. Cushing's syndrome due to abuse of betamethasone nasal drops. J Laryngol Otol. 102:1988;219-222.
104. Thorsson L., Edsbacker S., Conradson T.B. Lung deposition of budesonide from turbohaler is twice that from pressurized metered-dose inhaler (pMDI). Eur Respir J. 7:1994;1839-1844.
105. Thorsson L., Dahlstrom K., Edsbacker S., Kallen A., Paulson J., Wiren J.E. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol. 43:1997;155-161.
106. Tinkleman D.G., Reed C.E., Nelson H.S., Offord K.P. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics. 92:1993;64-77.
107. Todd G., Dunlop K., McNaboe J., Ryan M.F., Carson D., Shields M.D. Growth and adrenal suppression in asthmatic children treated with high dose fluticasone propionate. Lancet. 348:1996;27-29.
108. Toogood J.H., Baskerville J., Jennings B., Lefcoe N.M., Johansson S.A. Bioequivalent doses of assessment of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol. 84:1989;668-670.
109. Toogood J.H., Markov A.E., Baskerville J., Dyson C. Association of ocular cataracts with inhaled and oral steroid therapy during long-term treatment of asthma. J Allergy Clin Immunol. 91:1993;571-579.
110. van As A., Bronsky E.A., Dockhorn R.J., Grossman L., Lumry W., Meltzer E.O., Sletzer J.M., Rogenes P.R. Once daily fluticasone propionate is effective for perennial allergic rhinitis as twice daily BDP. J Allergy Clin Immunol. 91:1993;1146-1154.
111. Varsano I., Volovitz B., Malik H., Amir Y. Safety of 1 year treatment with budesonide in young children with asthma. J Allergy Clin Immunol. 85:1990;914-920.
112. Vaz R., Senior B., Morris M., Binkiewicz A. Adrenal effects of beclomethasone dipropionate inhalation therapy in asthmatic children. J Pediatr. 100:1982;660-662.
113. Wales D., McDowall P., Makker H., Kane J., O'Driscoll B.R. Systemic effects of high dose inhaled steroids (budesonide, beclomethasone dipropionate and fluticasone propionate). taken via large volume spacer. Thorax. 51(suppl. 3):1996;A71.
114. Whitaker K., Webb J., Barnes J., Barnes N.D. Effect of fluticasone propionate on growth in children with asthma. Lancet. 348:1996;63-64.
115. Wiksrom A.-C., Bakke O., Okret S., Bronnegard M., Gustafsson J.-A. Intracellular localisation of the glucocorticoid receptor, evidence for cytoplasmic and nuclear localization. Endocrinology. 120:1987;1232-1242.
116. Wilson A.M., McFarlane L.C., Lipworth B.J. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity. J Allergy Clin Immunol. 101:1998;470-474.
117. Wisniewski A.F., Lewis S.A., Green D.J., Maslanka W., Burrell H., Tattersfield A.E. A cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma. Thorax. 52:1997;853-860.
118. Wolthers O.D. Long-, intermediate- and short-term growth studies in asthmatic children treated with inhaled glucocorticoids. Eur Respir J. 9:1996;821-827.
119. Wolthers O.D., Pedersen S. Short term linear growth in asthmatic children during treatment with prednisolone. Br Med J. 301:1990;145-148.
120. Wolthers O.D., Pedersen S. Growth of asthmatic children during treatment with budesonide, a double blind trial. Br Med J. 303:1991;163-165.
121. Wolthers O.D., Pedersen S. Controlled study of linear growth in asthmatic children during treatment with inhaled corticosteroids. Pediatrics. 89:1992;839-842.
122. Wolthers O.D., Pedersen S. Short term growth during treatment with inhaled fluticasone propionate and beclomethasone dipropionate. Arch Dis Child. 68:1993;673-676. a.
123. Wolthers O.D., Pedersen S. Short term growth in children with allergic rhinitis treated with oral antihistamines, depot and intranasal glucocorticoids. Acta Paediatr. 82:1993;635-640. b.
124. Wolthers O.D., Pedersen S. Knemometry assessment of systemic activity of once daily intranasal dry-powder budesonide in children. Allergy. 49:1994;96-99.
125. Wolthers O.D., Hansen M., Juul A., Nielsen H.K., Pedersen S. Knemometry, urine cortisol excretion, and measures of the insulin-like growth factor axis and collagen turnover in children treated with inhaled glucocorticosteroids. Pediatr Res. 41:1997;44-50.
126. Wood S.M., Coulson R. Adverse drug reactions on-line information tracking (ADROIT). Pharm Med (Basingstoke). 7:1993;203-213.